Highlights from ASCO 2011-Denosumab versus zoledronic acid in patients with bone metastases from solid tumors other than breast and prostate cancers or multiple myeloma: A number needed to treat (NNT) analysis
Clinical Impact, from MDLinx , 06/08/2011
As previously reported fewer 1st or subsequent SREs occurred in patients receiving denosumab. This analysis suggests a relatively low NNT for each SRE prevented by denusomab. The low NNT for each SRE prevented shows the therapeutic efficacy for denosumab in these patients compared with ZA. Denosumab is a new treatment option for the prevention of SREs in advanced cancer patients with metastatic bone disease. Further cost–benefit analyses of denusomab trials are awaited.